Logo image of PHI1.DE

KONINKLIJKE PHILIPS NV (PHI1.DE) Stock Fundamental Analysis

FRA:PHI1 - Deutsche Boerse Ag - NL0000009538 - Common Stock - Currency: EUR

21.2  +0.46 (+2.22%)

Fundamental Rating

3

Overall PHI1 gets a fundamental rating of 3 out of 10. We evaluated PHI1 against 57 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of PHI1 have multiple concerns. PHI1 has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

PHI1 had positive earnings in the past year.
In multiple years PHI1 reported negative net income over the last 5 years.
Of the past 5 years PHI1 4 years had a positive operating cash flow.
PHI1.DE Yearly Net Income VS EBIT VS OCF VS FCFPHI1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

1.2 Ratios

PHI1's Return On Assets of 1.37% is in line compared to the rest of the industry. PHI1 outperforms 42.11% of its industry peers.
With a Return On Equity value of 3.19%, PHI1 perfoms like the industry average, outperforming 42.11% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 3.34%, PHI1 is doing worse than 61.40% of the companies in the same industry.
Industry RankSector Rank
ROA 1.37%
ROE 3.19%
ROIC 3.34%
ROA(3y)-3.08%
ROA(5y)1.15%
ROE(3y)-7.29%
ROE(5y)2.23%
ROIC(3y)N/A
ROIC(5y)N/A
PHI1.DE Yearly ROA, ROE, ROICPHI1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

1.3 Margins

The Profit Margin of PHI1 (2.07%) is comparable to the rest of the industry.
With a Operating Margin value of 5.39%, PHI1 is not doing good in the industry: 61.40% of the companies in the same industry are doing better.
PHI1's Operating Margin has declined in the last couple of years.
PHI1 has a worse Gross Margin (43.42%) than 66.67% of its industry peers.
In the last couple of years the Gross Margin of PHI1 has remained more or less at the same level.
Industry RankSector Rank
OM 5.39%
PM (TTM) 2.07%
GM 43.42%
OM growth 3Y-1.59%
OM growth 5Y-8.09%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.71%
GM growth 5Y1.08%
PHI1.DE Yearly Profit, Operating, Gross MarginsPHI1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PHI1 is destroying value.
Compared to 1 year ago, PHI1 has less shares outstanding
The number of shares outstanding for PHI1 has been increased compared to 5 years ago.
The debt/assets ratio for PHI1 is higher compared to a year ago.
PHI1.DE Yearly Shares OutstandingPHI1.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
PHI1.DE Yearly Total Debt VS Total AssetsPHI1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.2 Solvency

An Altman-Z score of 1.85 indicates that PHI1 is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 1.85, PHI1 perfoms like the industry average, outperforming 42.11% of the companies in the same industry.
PHI1 has a Debt/Equity ratio of 0.60. This is a neutral value indicating PHI1 is somewhat dependend on debt financing.
The Debt to Equity ratio of PHI1 (0.60) is worse than 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF N/A
Altman-Z 1.85
ROIC/WACC0.55
WACC6.12%
PHI1.DE Yearly LT Debt VS Equity VS FCFPHI1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B

2.3 Liquidity

PHI1 has a Current Ratio of 1.28. This is a normal value and indicates that PHI1 is financially healthy and should not expect problems in meeting its short term obligations.
PHI1 has a Current ratio of 1.28. This is in the lower half of the industry: PHI1 underperforms 66.67% of its industry peers.
PHI1 has a Quick Ratio of 1.28. This is a bad value and indicates that PHI1 is not financially healthy enough and could expect problems in meeting its short term obligations.
PHI1's Quick ratio of 0.79 is on the low side compared to the rest of the industry. PHI1 is outperformed by 68.42% of its industry peers.
Industry RankSector Rank
Current Ratio 1.28
Quick Ratio 0.79
PHI1.DE Yearly Current Assets VS Current LiabilitesPHI1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B

More info and screens

4

3. Growth

3.1 Past

PHI1 shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.45%.
Measured over the past years, PHI1 shows a decrease in Earnings Per Share. The EPS has been decreasing by -7.17% on average per year.
PHI1 shows a decrease in Revenue. In the last year, the revenue decreased by -0.89%.
PHI1 shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.00% yearly.
EPS 1Y (TTM)7.45%
EPS 3Y-5.66%
EPS 5Y-7.17%
EPS Q2Q%-3.85%
Revenue 1Y (TTM)-0.89%
Revenue growth 3Y1.65%
Revenue growth 5Y1%
Sales Q2Q%-0.99%

3.2 Future

PHI1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.40% yearly.
PHI1 is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.10% yearly.
EPS Next Y9.94%
EPS Next 2Y11.54%
EPS Next 3Y12.13%
EPS Next 5Y12.4%
Revenue Next Year1.15%
Revenue Next 2Y2.61%
Revenue Next 3Y3.12%
Revenue Next 5Y3.1%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PHI1.DE Yearly Revenue VS EstimatesPHI1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5B 10B 15B 20B 25B
PHI1.DE Yearly EPS VS EstimatesPHI1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0.5 1 1.5 2

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 15.36, which indicates a correct valuation of PHI1.
Based on the Price/Earnings ratio, PHI1 is valued cheaper than 89.47% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.48, PHI1 is valued a bit cheaper.
The Price/Forward Earnings ratio is 12.30, which indicates a correct valuation of PHI1.
PHI1's Price/Forward Earnings ratio is rather cheap when compared to the industry. PHI1 is cheaper than 82.46% of the companies in the same industry.
PHI1's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 36.52.
Industry RankSector Rank
PE 15.36
Fwd PE 12.3
PHI1.DE Price Earnings VS Forward Price EarningsPHI1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

PHI1's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. PHI1 is cheaper than 77.19% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 11.35
PHI1.DE Per share dataPHI1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

PHI1's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PHI1's earnings are expected to grow with 12.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.55
PEG (5Y)N/A
EPS Next 2Y11.54%
EPS Next 3Y12.13%

More info and screens

0

5. Dividend

5.1 Amount

PHI1 does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KONINKLIJKE PHILIPS NV

FRA:PHI1 (7/17/2025, 7:00:00 PM)

21.2

+0.46 (+2.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)07-29 2025-07-29
Inst Owners42.8%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap20.41B
Analysts73.08
Price Target26.42 (24.62%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)-70.49%
DP0.27%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.14%
Min EPS beat(2)-11.97%
Max EPS beat(2)22.24%
EPS beat(4)1
Avg EPS beat(4)-3.31%
Min EPS beat(4)-16.56%
Max EPS beat(4)22.24%
EPS beat(8)2
Avg EPS beat(8)-6.4%
EPS beat(12)4
Avg EPS beat(12)8.51%
EPS beat(16)5
Avg EPS beat(16)1.66%
Revenue beat(2)0
Avg Revenue beat(2)-2.5%
Min Revenue beat(2)-3.04%
Max Revenue beat(2)-1.96%
Revenue beat(4)0
Avg Revenue beat(4)-3.17%
Min Revenue beat(4)-5.22%
Max Revenue beat(4)-1.96%
Revenue beat(8)0
Avg Revenue beat(8)-3.16%
Revenue beat(12)2
Avg Revenue beat(12)-1.77%
Revenue beat(16)2
Avg Revenue beat(16)-1.84%
PT rev (1m)-2.75%
PT rev (3m)-8.86%
EPS NQ rev (1m)-6.21%
EPS NQ rev (3m)-22.91%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.31%
Revenue NQ rev (1m)-2.12%
Revenue NQ rev (3m)-5.2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.65%
Valuation
Industry RankSector Rank
PE 15.36
Fwd PE 12.3
P/S 1.14
P/FCF N/A
P/OCF N/A
P/B 1.75
P/tB N/A
EV/EBITDA 11.35
EPS(TTM)1.38
EY6.51%
EPS(NY)1.72
Fwd EY8.13%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS18.67
BVpS12.15
TBVpS-1.33
PEG (NY)1.55
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.37%
ROE 3.19%
ROCE 4.75%
ROIC 3.34%
ROICexc 3.55%
ROICexgc 10.93%
OM 5.39%
PM (TTM) 2.07%
GM 43.42%
FCFM N/A
ROA(3y)-3.08%
ROA(5y)1.15%
ROE(3y)-7.29%
ROE(5y)2.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y10.6%
ROICexcg growth 5Y-2.51%
ROICexc growth 3Y4.73%
ROICexc growth 5Y-6.98%
OM growth 3Y-1.59%
OM growth 5Y-8.09%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.71%
GM growth 5Y1.08%
F-ScoreN/A
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF N/A
Debt/EBITDA 2.99
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.28
Quick Ratio 0.79
Altman-Z 1.85
F-ScoreN/A
WACC6.12%
ROIC/WACC0.55
Cap/Depr(3y)50.01%
Cap/Depr(5y)53.78%
Cap/Sales(3y)3.94%
Cap/Sales(5y)4.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.45%
EPS 3Y-5.66%
EPS 5Y-7.17%
EPS Q2Q%-3.85%
EPS Next Y9.94%
EPS Next 2Y11.54%
EPS Next 3Y12.13%
EPS Next 5Y12.4%
Revenue 1Y (TTM)-0.89%
Revenue growth 3Y1.65%
Revenue growth 5Y1%
Sales Q2Q%-0.99%
Revenue Next Year1.15%
Revenue Next 2Y2.61%
Revenue Next 3Y3.12%
Revenue Next 5Y3.1%
EBIT growth 1Y379.25%
EBIT growth 3Y0.03%
EBIT growth 5Y-7.17%
EBIT Next Year50.08%
EBIT Next 3Y20.59%
EBIT Next 5YN/A
FCF growth 1Y-45.51%
FCF growth 3Y-40.93%
FCF growth 5Y-1.73%
OCF growth 1Y-31.12%
OCF growth 3Y-32.38%
OCF growth 5Y-4.03%